LCLavanya Challagundla

Lavanya Challagundla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lavanya Challagundla has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transcriptomic Profiling of the Amygdala of Children With Autism Spectrum Disorder

    by Jobin Babu, Ayushi Lal, Lavanya Challagundla, Obie Allen, Madeline Griffin, Barbara Gisabella, Harry Pantazopoulos

    A growing number of studies point to a key role of the amygdala in Autism Spectrum Disorders (ASD). The amygdala is involved in several processes in ASD including emotional valence, facial recognition, regulation of social learning, empathy, and anxiety. Brain imaging and postmortem studies demonstrate altered amygdala development in children with ASD, associated with impairment in social behavior and anxiety. There is limited information regarding the molecular pathology of the amygdala in children with ASD. We conducted RNAseq profiling on postmortem amygdala samples from male children (4–14 years old) with ASD ( n = 8) and normotypic male children ( n = 6). Furthermore, we conducted drug repurposing analysis to identify compounds predicted to reverse the transcriptomic signatures identified in order to identify potential therapeutic targets for development of early intervention treatments. Full transcriptome gene expression profiling implicated molecular pathways involved in neuroimmune signaling, glycogen and carbohydrate metabolism, matrix metalloproteases, neurodevelopment, estrogen receptor signaling, and synaptic signaling. Targeted pathway analysis of the top 10% of genes ranked by log 2 fold change implicated pathways involved in extracellular matrix organization (ECM), immune signaling, and synaptic signaling. Our drug repurposing analysis identified sleep modifying compounds and anti‐inflammatory compounds including COX2 and GSK3 inhibitors amongst the top predicted therapeutic compounds. PDGF receptor tyrosine kinase inhibitors were identified as a top potential therapeutic mechanism of action. Collectively, we identified alterations in immune signaling, ECM, and synaptic signaling in the amygdala of children with ASD. Furthermore, our findings highlight a number of potential therapeutic drug targets for development of early intervention strategies.

  • Systemic and Proximal Tubule Specific Knockout of Arhgef11 and Impact on Hypertension and Kidney Injury

    by Wenjie Wu, Lavanya Challagundla, Andrew R. Milner, Michael R. Garrett, Ashley C. Johnson

    Hypertension is a progressive condition that predisposes patients to the development of chronic kidney disease (CKD). Previous genetic and animal studies utilizing the Dahl salt-sensitive (SS) rat, a genetic model of progressive hypertension and CKD, identified that Arhgef11 was playing a role in hypertension and CKD in the Dahl SS model. Arhgef11 is a Rho guanine nucleotide exchange factor involved in the regulation of the cytoskeleton, intracellular trafficking, protein-protein interactions, and transcription factor regulation. Temporal evaluation of SS-WT and SS- Arhgef11 -/- rats demonstrated that the loss of Arhgef11 attenuated hypertension and improved renal function. Transcriptome and proteomic studies lead to the hypothesis that dysregulation of these pathways in the kidney, particularly the proximal tubule, may alter sodium handling and ultimately lead to hypertension. Current rat studies confirmed previous work between SS-WT and SS- Arhgef11 -/- and investigated early (week 4) transcriptional changes using single nuclei RNA sequencing, present before blood pressure differences are observed. Due to only being able to test systemic loss of Arhgef11 in the rat model, a global knockout ( Arhgef11 -/- (CMV) ), as well as a proximal tubule-specific deletion ( Arhgef11 -/- (Sglt2) ) were studied in the mouse. Studies utilized two models of experimental hypertension: Angiotensin II and deoxycorticosterone acetate (DOCA) + salt. Both models demonstrated a slight protective effect on blood pressure and kidney injury for DOCA experimental models, replicating the rat knockout data. However, the impact of the loss of Arhgef11 was dependent on the type of induced hypertension, with the large effect in the rat model likely explained by the highly permissive genetic background of the Dahl SS model.


  • Open Access

    Methylseq, single-nuclei RNAseq, and discovery proteomics identify pathways associated with nephron-deficit CKD in the HSRA rat model

    by Andrew R. Milner, Ashley C. Johnson, Esinam M. Attipoe, Wenjie Wu, Lavanya Challagundla, Michael R. Garrett

    The HSRA rat is a novel model of nephron deficiency and provides a unique opportunity to study the association between nephron number and chronic kidney disease (CKD). Previous work characterized the impact of age, hypertension, and diabetes on the development of CKD in HSRA animals. This study examined early changes in epigenetics, cell-type specific transcriptome, and proteomic changes in the kidney that likely predispose the model to CKD with age.


  • Temporal shifts to the gut microbiome associated with cognitive dysfunction following high-fat diet consumption in a juvenile model of traumatic brain injury

    by Allie M. Smith, Lavanya Challagundla, Ian G. McGee, Zyra J. Warfield, Christiano Dos Santos E. Santos, Michael R. Garrett, Bernadette E. Grayson

    Traumatic brain injury (TBI) produces memory and learning difficulties. Diet profoundly influences the populations of gut microbiota. Following traumatic brain injury in a pediatric model consuming either a healthy or high-fat diet (HFD), significant shifts in bacterial populations occur, of which, some are associated with diet, whereas others are associated with neurocognitive performance. More work is needed to determine whether these microbes can therapeutically improve learning following trauma to the brain.